A former senior executive at Novartis AG generics unit Sandoz pleaded guilty on Friday for conspiring to fix prices of generic drugs, the latest in a long-running US criminal antitrust probe, reported Bloomberg.
Hector Armando Kellum, who was responsible for overseeing generic-drug prices and contracts at Sandoz, a New Jersey-based generic and biosimilar company run by the Swiss pharmaceutical giant, pleaded guilty to conspiring with other drug executives to fix prices from 2013 to 2015.
Kellum allegedly conspired to set prices and rig bids for off-patent drugs with former Taro Pharmaceutical Industries Ltd. marketing executive Ara Aprahamian, who was indicted in the probe earlier this month, the Justice Department said.
“With today’s guilty plea, the Antitrust Division continues its prosecution of high-ranking executives who conspired to cheat America’s most vulnerable elderly consumers by raising prices for vital drugs,” said Makan Delrahim, the head of the division, in a statement.
Kellum is the fourth executive to be charged and the third to plead guilty in an investigation that began more than five years ago and has scrutinized the alleged behavior of executives at some of the world’s largest generic-drug makers, including Mylan and Teva Pharmaceutical Industries. Two smaller manufacturers, Heritage Pharmaceuticals and Rising Pharmaceuticals, settled Justice Department charges with what’s known as a deferred prosecution agreement last year.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI